Mehandziska Sanja, Stajkovska Aleksandra, Stavrevska Margarita, Jakovleva Kristina, Janevska Marija, Rosalia Rodney, Kungulovski Ivan, Mitrev Zan, Kungulovski Goran
Zan Mitrev Clinic, Skopje, Macedonia.
Bio Engineering LLC, Skopje, Macedonia.
Front Genet. 2020 Jun 30;11:619. doi: 10.3389/fgene.2020.00619. eCollection 2020.
To enable the implementation of precise genomics in a local healthcare system, we devised a pipeline for filtering and reporting of relevant genetic information to healthy individuals based on exome or genome data. In our analytical pipeline, the first tier of filtering is variant-centric, and it is based on the selection of annotated pathogenic, protective, risk factor, and drug response variants, and their one-by-one detailed evaluation. This is followed by a second-tier gene-centric deconstruction and filtering of virtual gene lists associated with diseases, and VUS-centric filtering according to ACMG pathogenicity criteria and pre-defined deleteriousness criteria. By applying this filtering protocol, we were able to provide valuable insights regarding the carrier status, pharmacogenetic profile, actionable cardiovascular and cancer predispositions, and potentially pathogenic variants of unknown significance to our patients. Our experience demonstrates that genomic profiling can be implemented into routine healthcare and provide information of medical significance.
为了在本地医疗系统中实现精准基因组学,我们设计了一个流程,用于根据外显子组或基因组数据筛选并向健康个体报告相关遗传信息。在我们的分析流程中,第一层筛选是以变异为中心的,它基于对已注释的致病性、保护性、风险因素和药物反应变异的选择,以及对它们逐一进行的详细评估。接下来是第二层以基因为中心的解构和对与疾病相关的虚拟基因列表的筛选,以及根据美国医学遗传学与基因组学学会(ACMG)致病性标准和预定义有害性标准以意义未明变异(VUS)为中心的筛选。通过应用此筛选方案,我们能够为患者提供有关携带者状态、药物遗传学概况、可采取行动的心血管和癌症易感性以及意义未明的潜在致病变异的有价值见解。我们的经验表明,基因组分析可以应用于常规医疗保健并提供具有医学意义的信息。